Tesamorelin + Ipamorelin 13

Tesamorelin + Ipamorelin 13 is a research-compound blend of 10 mg tesamorelin and 3 mg ipamorelin in a 13 mg vial (sold as "13mg"; not the 16 mg vial labeled "13/3").

Mixed with 3 mL of bacteriostatic water it is dosed in insulin units: 10 units to start (tesamorelin 0.33 · ipamorelin 0.1 mg), 20 units (0.67 · 0.2 mg) and 30 units at the top (tesamorelin 1 · ipamorelin 0.3 mg), nightly at bedtime while fasted.

Best for

Growth-hormone-axis research that wants tesamorelin to reach its lowest trial dose (1 mg) without taking ipamorelin past its own 300 mcg top — the 30-unit rung sits on both. Because its concentration differs from the 10 and 16 mg vials, their unit numbers do not transfer.

What to expect

Ipamorelin's GH pulse follows each injection within hours. The 30-unit top gives tesamorelin 1 mg, the lower arm of its dose-ranging trial, where trunk-fat loss reached significance only at 2 mg over 12 weeks.

Pairs with

Already a two-receptor GH-axis stack (a GHRH analog plus a ghrelin-receptor agonist): adding another GH secretagogue doubles the same pathway, so it is usually run standalone.

Research protocol

Subcutaneous injection nightly at bedtime, fasted (no food ~2 h before), 5 nights a week; 12 weeks on, 4 off. Reconstitute the 13 mg vial with 3 mL BAC water (~3.33 mg/mL tesamorelin, 1 mg/mL ipamorelin).

A vial already mixed at 2 mL draws 6 / 13 / 20 units for about the same doses (round down, never up).

The ladder reads in mg per compound: 10 units = tesamorelin 0.33 · ipamorelin 0.1 mg, 20 units = 0.67 · 0.2 mg, 30 units = 1 · 0.3 mg. Specific dosing varies by goal and physician guidance.

Typical research dosing

Typical start10 unitsstarting · bedtime, fastedTesamorelin 0.33 · Ipamorelin 0.1 mg20 unitsstandardTesamorelin 0.67 · Ipamorelin 0.2 mg30 unitstop of rangeTesamorelin 1 · Ipamorelin 0.3 mg

How often: 5 days on / 2 off
When: Bedtime · Fasted
Route: Subcutaneous
Vial & water: 13 mg in 3 mL · 10 units ≈ 0.33 mg Tesamorelin + 0.1 mg Ipamorelin
Cycle: 12 weeks on, 4 weeks off is a common pattern for growth-hormone secretagogue blends

CautionDIFFERENT PRODUCT FROM TESAMORELIN + IPAMORELIN 16 — 10 mg / 3 mg here against 13 mg / 3 mg there. Vendors sell both as "13": the 16 is labeled "13/3" (13 mg of tesamorelin), this vial "13mg" in total. Check your label's split before choosing. Already mixed at 2 mL? Draw 6 / 13 / 20 units for about the same 0.1 / 0.2 / 0.3 mg ipamorelin (round down, never up). Set the vial (13 mg) and your water when you reconstitute. Monitor IGF-1 and glucose; see the component peptide pages.

The same numbers the goodtides app and the Dose Calc use — a research reference, not a prescription. Responses are individual; research protocols start at the low end.

How it works

Tesamorelin is a stabilized synthetic analog of growth-hormone-releasing hormone (GHRH) that stimulates pituitary GH release through the GHRH receptor; it is FDA-approved (as Egrifta) only for excess abdominal fat in HIV-associated lipodystrophy, where its trials gave 1–2 mg a day.

No study of this combination exists, and ipamorelin is not FDA-approved, so this is a research-context blend.

Ipamorelin is a pentapeptide ghrelin-receptor (GHS-R1a) agonist that, in rats and pigs, released GH without the ACTH or cortisol rise of older secretagogues; its human studies are intravenous, and there is no published under-the-skin dose-finding study. The two act on complementary receptors.

References7

Tracking Tesamorelin + Ipamorelin 13?

Log every dose, count every vial, and verify your batches — free in the goodtides app.

Get the app

This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.